SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-150303
Filing Date
2022-05-13
Accepted
2022-05-13 17:27:15
Documents
12
Period of Report
2022-05-12
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d721313d8k.htm   iXBRL 8-K 34940
  Complete submission text file 0001193125-22-150303.txt   155820

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA akba-20220512.xsd EX-101.SCH 2842
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20220512_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20220512_pre.xml EX-101.PRE 10803
6 EXTRACTED XBRL INSTANCE DOCUMENT d721313d8k_htm.xml XML 3230
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 22924156
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences